Ascentawits Pharmaceuticals
Ascentawits Pharmaceuticals is a China-based biotechnology company running 2 late-stage cancer trials of AST-3424 and AST-001 in hepatocellular carcinoma and pancreatic ductal adenocarcinoma.
Overview
Ascentawits Pharmaceuticals, based in Shenzhen, China, is a biotechnology company. Ascentawits Pharmaceuticals (Shenzhen Ascenta Wits Pharmaceutical Technology Co., Ltd.) develops small molecule-drug conjugates as targeted cancer therapeutics. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing AST-3424 and AST-001 in hepatocellular carcinoma and pancreatic ductal adenocarcinoma. The largest, NCT06245330 (A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumours), plans to enrol 180 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyCEBIOTEX
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-sponsor.
- CompanyCatalYm
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyShanghai AbelZeta
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyCivaTech Oncology
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-sponsor.
- CompanyCrinetics Pharmaceuticals
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-sponsor.
- CompanyOrion, Orion Pharma
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-sponsor.
- CompanyOncolytics Biotech
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-sponsor.
- CompanyMBrace Therapeutics
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-sponsor.